Dr. Heery on Advancements in Treatment of Neuroendocrine Tumors

Christopher Heery, MD
Published: Saturday, Apr 23, 2016



Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors (NETs).

Over the past few years, research has demonstrated that agents used to control the symptoms of NETs could also be used to control disease. Also, Heery says, the combination of radionuclides and other experimental agents may become the backbone of future therapy.

Select subgroups of patients with NETs could also experience positive outcomes with agents such as everolimus (Afinitor) and sunitinib (Sutent).

<<< View more from the 2016 School of Gastrointestinal Oncology



Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors (NETs).

Over the past few years, research has demonstrated that agents used to control the symptoms of NETs could also be used to control disease. Also, Heery says, the combination of radionuclides and other experimental agents may become the backbone of future therapy.

Select subgroups of patients with NETs could also experience positive outcomes with agents such as everolimus (Afinitor) and sunitinib (Sutent).

<<< View more from the 2016 School of Gastrointestinal Oncology


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x